Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications[E8]

Aus der Bekanntmachung

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products [1] ) and enhanced health outcomes by ensuring safer and more effective use of medication. Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities. Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines. Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by robust evidence. Educational programs for healthcare providers and patients benefit from improved awareness and management of polypharmacy and ADRs. Scope: While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that ar…[E3]

Die Angaben der Bekanntmachung werden so gezeigt, wie die Quelle sie veröffentlicht hat. Die Fakten und Anforderungen, die wir herausziehen, sind auf Englisch.

• Offen fürUniversities and research. Von SLETOR anhand der Wörter der Ausschreibung zugeordnet.
• BedingungEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• RisikoThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• UnbekanntWe read the funder's listing, not the full guidance or application forms.

1. Für Angebote geöffnet · 29. Okt. 2026, 07:41 UTC

   The funder published the call with a future closing date.

   Geändert: status, notice type, published at (Quelldatensatz Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02))

2. Erstmals gesehen · 28. Okt. 2026, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   Quelldatensatz: Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02)

Jede Angabe auf dieser Seite stammt aus der Ausschreibung des Fördergebers. Jeder Eintrag zeigt den Datensatz und das Feld, aus dem er gelesen wurde.

1. E1

   The funder is European Commission.

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/type/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/deadlineDate/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to d…”

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/descriptionByte/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/type/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

5. E5

   This is an EU call for proposals.

   “31094502”

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/status/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/startDate/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/status/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

8. E8

   The notice is titled "Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications".

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/title/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   Aus Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), Feld /metadata/budgetOverview/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Datenlizenz: Creative Commons Attribution 4.0 (European Commission) ↗ (öffnet in neuem Tab). Persönliche Kontaktdaten aus Bekanntmachungen werden weder gespeichert noch angezeigt.